The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1535
December 4, 2017
View Complete Issue         Table of Contents 2019 
Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
December 4, 2017 (Issue: 1535)
The FDA has approved an extended-release (ER) capsule formulation of amantadine (Gocovri – Adamas) for once-daily treatment of levodopa-induced dyskinesia in patients with Parkinson's disease (PD). It is the first product to be approved in the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
Article code: 1535c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.